ACADACADIA Pharmaceuticals Inc.

$4B

Q1 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$115M+8.4% YoY

Gross Profit

$113M97.4% margin

Operating Income

-$113M-97.9% margin

Net Income

-$113M-97.9% margin

EPS (Diluted)

$-0.70

QoQ Revenue Growth

-11.7%

Cash Flow

Operating Cash Flow

-$76M

Free Cash Flow

-$76M

Stock-Based Comp.

$15M

Balance Sheet

Total Assets

$624M

Total Liabilities

$179M

Stockholders' Equity

$445M

Cash & Equivalents

$205M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$115M	$107M	+8.4%
Gross Profit	$113M	$102M	+10.5%
Operating Income	-$113M	-$67M	-69.3%
Net Income	-$113M	-$66M	-70.1%

ACAD Q1 2022 Earnings — ACADIA Pharmaceuticals Inc. Revenue & Financial Results | Market Cap Arena